News | Breast Imaging | June 28, 2017

Laser Imaging "Bowl" to Give Instant Test for Breast Cancer

European scientists developing photoacoustic imaging system to increase patient comfort and shorten the diagnostic process

Laser Imaging "Bowl" to Give Instant Test for Breast Cancer

June 28, 2017 — In a bid to make the world's first while-you-wait test for breast cancer, European scientists are developing a comfortable hemispherical bowl lined with laser sources and ultrasound detectors with the potential to reduce the stages in spotting the disease into a single appointment.

Current breast cancer diagnosis can be distressing and painful over a number of weeks. Multiple stages can involve visiting a general practitioner, being sent to a specialist for an X-ray mammogram, having an ultrasound, before undergoing a needle, a punch or a vacuum assisted biopsy, as well as placing one breast at a time between two metal plates in a painful clamp.

However, a new imaging system being developed by scientists at the University of Twente in the Netherlands intends to remove the discomfort and uncertainty involved in a diagnosis.

The device employs both light and sound together in a technique called photoacoustics, combining lasers and photonics with ultrasound detection.

The size of a hospital bed, a patient lies face down placing their breast snugly into the ‘reader’, a hemispherical ‘bowl’ lined with up to a hundred optical fibers and several ultrasound detectors.

Multiple images of a suspect breast and tumor are then acquired from dozens of different angles before assembling the multiple shots into a single 3-D image. 

The ‘PAMMOTH’ (Photoacoustic Ultrasound Mammoscopy for evaluating screening-detected abnormalities in the breast), hopes to lead the researchers into photoacoustic, real-time 3-D imaging of suspicious lesions.

Project coordinator Srirang Manohar explained, “We are creating an imaging device that we hope will reduce all of the stages involved in spotting breast cancer into one convenient appointment in order to reduce time, uncertainty and the number of unnecessary biopsies. We intend to make breast cancer diagnosis a one-stop-shop, while you wait.”

It works by sending short pulses of light into the breast towards the suspected lesion. Some of the delivered energy will be absorbed in the tissue and converted into heat, leading to transient thermoelastic expansion, or a mechanical ‘push’ signal from the suspected tumor.

Ultrasound detectors on the surface of the breast, from the hemispherical reader bowl where the breast is placed, can then detect and measure these push signals before analyzing them on-site. Here the imager can look into the hemoglobin (the oxygen-carrying protein in the blood) activity within the suspected tumor.

Since tumors consume oxygen at high rates to survive, lower oxygenation levels around a suspect lesion could tell a physician that a suspect lump is more likely to be a malignant growth than not.

The imager employs a multi-wavelength illumination in the near-infrared wavelength region to extract information about blood oxygenation, using PAMMOTH’s own image reconstruction methods.

As part of the PAMMOTH team, researchers at University College London (UCL) are working on the mathematics, the image reconstruction and the analysis of the signals to determine how aggressive a tumor could be.

By gathering key information about the hemoglobin and oxygenation levels to and from the suspected tumor, the user could diagnose how likely it would be for the tumor to spread or whether it was simply benign.

“An aggressive tumor has a high metabolism and consumes oxygen more rapidly than normal tissue or a benign lesion. Our instrument and the mathematical approaches we are developing could allow us to check the oxygen saturation rate accurately,” said Manohar. “If a patient’s oxygen saturation rate was found to be considerably lower than surrounding tissue then we could pinpoint where an aggressive tumor could be, and radiologists could understand how the tumor is likely to behave.”

Current techniques to diagnose breast cancer such as X-ray mammography, ultrasound or magnetic resonance imaging (MRI) scans can sometimes fail to spot a tumor from healthy tissue or a benign abnormality, resulting in tumors that are missed and unnecessary biopsies being carried out.

Unnecessary biopsies and risks of false positives in breast cancer diagnosis are hotly contested topics among medical experts. As well as the untold stress and discomfort experienced by women all over the world by unnecessary treatments, inefficient diagnoses have an extremely worrying cost implication.

Every year in the United States alone, $4 billion is spent on false-positive mammograms and breast cancer over diagnosis among women ages 40-59, according to research published in Health Affairs. A similar picture is played out across Europe with millions of Euros being spent on unnecessary mammograms.

“A prime focus of the PAMMOTH project is to develop an imager and data analysis to be able to intervene at a very early stage. We need to be able to say whether a suspect lesion is good or bad. This technique would have a substantial impact upon the money spent on unnecessary biopsies, as well as to remove the trauma involved in a diagnosis for women around the world,” said Manohar.

The PAMMOTH team hopes to have a prototype ready for 2020 ready for completion in 2021.

Coordinated in the Netherlands at the University of Twente, the PAMMOTH project received a grant of €4,352,007.50 from Horizon 2020 via the Photonics Public Private Partnership.

For more information: www.photonics21.org

Related Content

A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms.

A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms. Images from Christiane Kuhl, M.D.

Feature | MRI Breast | March 04, 2021 | By Dave Fornell, Editor
Dense breast tissue can hide cancers i
Researchers said women who skip even one scheduled mammography screening before a breast cancer diagnosis face a significantly higher risk of dying from the cancer.

Getty Images

News | Mammography | March 03, 2021
March 3, 2021 — Attendance at regular ...
55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned. #COVIDvaccine #COVID19

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned.

News | Breast Imaging | February 24, 2021
Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in

Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in (a). The bottom row focuses on the detection of small calcifications, a key feature in DCIS. These are undetectable in (d), detected in (e), enhanced in the maximum intensity projection (MIP) image at the bottom of (f), and confirmed by histopathology in the top part of (f). The scale bar [shown in (b) and (e)] is the same for all images apart from (f), which has its own scale. Red arrows in (e) and (f) indicate the microcalcifications. Image courtesy of Professor Alessandro Olivo

News | Breast Imaging | February 22, 2021
February 22, 2021 — A new X-ray imaging scanne
F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

News | Molecular Imaging | February 22, 2021
February 22, 2021 — Molecular imaging
Screening strategy based on baseline breast density at age 40 may be effective and cost-effective for reducing breast cancer mortality

Getty Images

News | Breast Density | February 10, 2021
February 10, 2021 — A mammography screenin...
Comparison of breast cancer mortality rates (red squares) and distant-stage breast cancer incidence rates from SEER9 (blue dots) and SEER18 (green dots) per 100,000 for white women aged, A, 20–39, B, 40–69, and, C, 70–79 years (3,7,8).

Comparison of breast cancer mortality rates (red squares) and distant-stage breast cancer incidence rates from SEER9 (blue dots) and SEER18 (green dots) per 100,000 for white women aged, A, 20–39, B, 40–69, and, C, 70–79 years (3,7,8). Image courtesy of Radiology 

News | Breast Imaging | February 10, 2021
February 10, 2021 — Breast cancer death rates have stopped declining for women in the U.S.
After acquiring the molecular breast imaging (MBI) assets from GE Healthcare and Dilon Technologies, Inc., SmartBreast Corporation (SmartBreast), a privately held company focused on breast cancer screening and diagnosis, announced today that it has formed a partnership with FoxSemicon Integrated Technologies, Inc. (FITI) to manufacture molecular breast imaging (MBI) systems.
News | Breast Imaging | February 09, 2021
February 9, 2021 — After acquiring the...

Chart courtesy of the American Cancer Society

News | Breast Imaging | February 08, 2021
February 8, 2021 — Cancer ranks as a leading cause of death in every country in the world, and, for the first time,